Corporate governance
How the Board of Solvonis Therapeutics plc is structured, the governance code it applies and how the Company communicates with its shareholders.
Board structure and leadership
The Board has one executive and four non-executive directors. The Chair is responsible for the effectiveness of the Board and is the primary contact with shareholders. Execution of the Company’s strategy is reserved for the Chief Executive Officer. Matters reserved for the Board’s approval are set out in a formal schedule.
QCA Corporate Governance Code
Solvonis applies the Quoted Companies Alliance (QCA) Corporate Governance Code. The corporate governance report explains how the Company applies each of the Code’s ten principles, and where and why it departs from them.
The Board established an Audit and Risk Committee after the 2025 year end; its terms of reference are below. Until then, as the 2025 corporate governance report describes, the Board considered audit and risk matters as a whole. There is no remuneration or nomination committee: the Board considers those matters as a whole, which it believes is appropriate for the Company’s stage of development.
This information was last reviewed in October 2026.
How we keep shareholders informed
Announcements are made through a Regulatory Information Service (RNS), and RNS announcements prevail over this website. Reports, presentations and meeting documents are published in the Investors section.